Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study on the Safety, Tolerability, and Preliminary Efficacy of EH002 in the Treatment of DFNB9 Congenital Deafness

NCT06722170 is registered in ClinicalTrials.gov with Yilai Shu as lead sponsor.

NCT NCT06722170
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06722170 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study on the Safety, Tolerability, and Preliminary Efficacy of EH002 in the Treatment of DFNB9 Congenital Deafness
Lead sponsor
Yilai Shu
Phase
Not applicable
Overall status
Recruiting
Start date
November 22, 2024
Completion date
November 30, 2029
Enrollment
24 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

congenital hearing loss, dfnb9, hearing loss, sensorineural